Lion Biotechnologies’ (LBIO) “Buy” Rating Reaffirmed at Roth Capital
Roth Capital reissued their buy rating on shares of Lion Biotechnologies Inc. (NASDAQ:LBIO) in a research note published on Monday morning. They currently have a $15.00 price objective on the biotechnology company’s stock.
LBIO has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Lion Biotechnologies from a hold rating to a sell rating in a research report on Wednesday, November 9th. Jefferies Group reissued a buy rating and set a $13.00 target price on shares of Lion Biotechnologies in a research report on Monday, November 7th. Cowen and Company reissued a buy rating on shares of Lion Biotechnologies in a research report on Friday, November 4th. Finally, Chardan Capital set a $20.00 target price on shares of Lion Biotechnologies and gave the stock a buy rating in a research report on Sunday, August 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $18.29.
Lion Biotechnologies (NASDAQ:LBIO) opened at 6.95 on Monday. The company’s 50-day moving average price is $6.74 and its 200-day moving average price is $7.62. The firm’s market cap is $431.50 million. Lion Biotechnologies has a 52-week low of $4.24 and a 52-week high of $9.58.
COPYRIGHT VIOLATION WARNING: This piece was originally published by Financial Market News and is owned by of Financial Market News. If you are accessing this piece on another website, it was illegally copied and republished in violation of US & international copyright and trademark law. The legal version of this piece can be viewed at http://www.financial-market-news.com/lion-biotechnologies-lbio-buy-rating-reaffirmed-at-roth-capital/1208191/.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. KCG Holdings Inc. acquired a new stake in Lion Biotechnologies during the third quarter worth $101,000. Quantitative Investment Management LLC acquired a new stake in Lion Biotechnologies during the second quarter worth $117,000. Stevens Capital Management LP acquired a new stake in Lion Biotechnologies during the third quarter worth $118,000. TD Asset Management Inc. acquired a new stake in Lion Biotechnologies during the third quarter worth $123,000. Finally, Geduld E E boosted its stake in Lion Biotechnologies by 50.0% in the third quarter. Geduld E E now owns 15,000 shares of the biotechnology company’s stock worth $123,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 79.62% of the company’s stock.
About Lion Biotechnologies
Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.